Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 9,283 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy
Interventions
amikacin/fosfomycin
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Canavan Disease
Interventions
rAAV-Olig001-ASPA, Levetiracetam, Prednisone
Drug
Lead sponsor
Myrtelle Inc.
Industry
Eligibility
3 Months to 60 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Conditions
Cystic Fibrosis
Interventions
Lefamulin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Kansas City, Kansas • Boston, Massachusetts • Valhalla, New York + 3 more
Conditions
Healthy
Interventions
ABT-384, Matching placebo to ABT-384
Drug
Lead sponsor
Abbott
Industry
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Orlando, Florida
Completed No phase listed Observational Accepts healthy volunteers

Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1

NCT00671229
Conditions
Healthy, Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 40 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Healthy Volunteer
Interventions
ipatasertib (Capsule), ipatasertib (Tablet)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

NCT05645757
Conditions
Bacterial Infection
Interventions
Ertapenem, Placebo, WCK 6777, Zidebactam
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Hepatitis C
Interventions
On Plan
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Healthy
Interventions
Surufatinib, Itraconazole
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Healthy, Chronic Stable Illness
Interventions
Casirivimab+Imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Winter Park, Florida
Conditions
EMR Ulcer
Interventions
Secretrol
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Breast Neoplasms
Interventions
Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
71
States / cities
Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4515100 in Healthy Participants

NCT07339722
Conditions
Healthy
Interventions
LY4515100 via SAD, LY4515100 via MAD, LY4515100, Itraconazole, Caffeine, Digoxin, Iohexol, Metformin, Rosuvastatin, Placebo, Midazolam, Levonorgestrel, Ethinyl Estradiol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
ganetespib, paclitaxel, trastuzumab, pertuzumab
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
New York, New York
Conditions
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
Interventions
Alomfilimab, Atezolizumab
Drug
Lead sponsor
Kymab Limited
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more
Conditions
Advanced CEACAM6-expressing Solid Tumors
Interventions
BAY1834942
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
XL844
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Duarte, California • San Diego, California • Houston, Texas
Conditions
Cancer
Interventions
XL765 (SAR245409)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Detroit, Michigan • Omaha, Nebraska • San Antonio, Texas
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

NCT07516405
Conditions
Healthy Volunteer, Older Adults (65-85 Years)
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Conditions
Huntington Disease
Interventions
SPK-10001, Placebo Surgery Control
Genetic · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
5
States / cities
Boston, Massachusetts • Cincinnati, Ohio • Columbus, Ohio + 2 more
Active, not recruiting Phase 1 Interventional Results available

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922
Conditions
Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma, Gastroesophageal Junction
Interventions
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic · Radiation
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Spinal Cord Neoplasm, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ispinesib, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Arcadia, California
Conditions
Obesity
Interventions
Peptide YY3-36
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
New Haven, Connecticut